Kolon TissueGene saw its stock price plummet 20.28% on the 16th to 62,100 won, closing at a sharp decline ahead of the company's TG-C Phase 3 clinical trial results announcement scheduled for this month. The drop occurred despite intraday gains, with trading volume surging in the afternoon and prices falling as low as 56,600 won. Market participants raised concerns about potential data leakage, though company officials stated that data compilation remains incomplete and results are not yet known. The decline reflects investor anxiety over whether TG-C will demonstrate structural improvement in osteoarthritis treatment, a key requirement for securing world-first disease-modifying osteoarthritis drug (DMOAD) approval from the US Food and Drug Administration.
Kolon TissueGene Stock Drops 20.28% on the 16th
According to the Korea Exchange on the 19th, Kolon TissueGene's stock price closed at 62,100 won on the 16th, down 15,800 won (-20.28%) from the previous trading day's closing price. The stock had risen to 80,500 won (+3.34%) during the day but plunged to 56,600 won (-27.35%) around 2:30 PM as trading volume surged. A company official confirmed that the Phase 3 results will be announced this month but stated that "the results are not yet known."
TG-C Targets World-First Fundamental Osteoarthritis Treatment Approval
Kolon TissueGene aims to secure approval as the world's first disease-modifying osteoarthritis drug (DMOAD) following the TG-C Phase 3 trial announcement. TG-C is a cell and gene therapy designed to restore cartilage structure itself through a single injection in patients with knee osteoarthritis. The global osteoarthritis treatment market is valued at approximately 14 trillion won, but no fundamental cure currently exists. To obtain DMOAD approval from the FDA, the drug must demonstrate safety along with pain improvement, functional improvement, and structural improvement simultaneously. TG-C has already confirmed statistically significant knee pain and functional improvement compared to the control group in US Phase 2 trials and domestic Phase 3 trials.
FDA Approval Possible Even Without Structural Improvement Proof
Analysts indicate that even in a worst-case scenario where TG-C fails to prove structural improvement in this Phase 3 trial, FDA approval remains possible as a pain treatment. Multiple treatments that alleviate pain or inflammation are already on the market. Lee Ji-soo, a researcher at Daol Investment & Securities, stated: "If structural improvement is proven in the US Phase 3 trial, the company can secure an exclusive market position as the world's first fundamental treatment," adding "even if partial success is achieved, FDA approval can be obtained even if it is not a fundamental treatment."
FAQ
What happened to Kolon TissueGene stocks on the 16th?
Kolon TissueGene's stock price fell 20.28% on the 16th, closing at 62,100 won. The stock had risen to 80,500 won during the day but dropped to as low as 56,600 won in the afternoon as trading volume surged.
Why did Kolon TissueGene stocks decline ahead of TG-C results?
The decline occurred due to investor concerns ahead of the TG-C Phase 3 clinical trial results announcement scheduled for this month. The results will determine whether TG-C can demonstrate structural improvement in osteoarthritis treatment, a requirement for world-first DMOAD approval from the FDA.
Can TG-C receive FDA approval without proving structural improvement?
According to analyst Lee Ji-soo at Daol Investment & Securities, FDA approval remains possible even without structural improvement proof, as TG-C has already demonstrated statistically significant pain and functional improvement in previous trials. Multiple pain-alleviating treatments are already approved in the market.
